Partner With Us NRI

Rossari Biotech Ltd

Company details

6M Return -28.23%
1Y Return -42.94%
Mkt Cap.(Cr) 3,768.81
Volume 15,750
Div Yield 0.07%
OI Chg %
Volume 15,750

Open Free Demat Account Online with ICICIDIRECT

Rossari Biotech Ltd.

Q3FY23 Quarterly Result Announced for Rossari Biotech Ltd.

Specialty chemical firm Rossari Biotech announced Q3FY23 results:

  • Consolidated Q3FY23 vs Q2FY23:
    • Revenue from operations stood at Rs 389.3 crore as against Rs 425.4 crore.
    • EBITDA at Rs 54.2 crore as against Rs 56.5 crore.
      • EBITDA margin at 13.9% as against 13.3%
    • PAT stood at Rs 25.7 crore as against Rs 23.9 crore.
    • EPS (Diluted) stood at Rs 4.6 as against Rs 4.3. 
  • Consolidated 9MFY23:
    • Revenue from operations stood at Rs 1,249.4 crore as against Rs 1,044.0 crore.
    • EBITDA at Rs 168.4 crore as against Rs 131.1 crore.
      • EBITDA margin at 13.5% as against 12.6%.
    • PAT stood at Rs 78.3 crore as against Rs 73.3 crore.
    • EPS (Diluted) stood at Rs 14.1 as against Rs 13.3.
  • Standalone Q3FY23 vs Q2FY23:
    • Revenue from operations stood at Rs 236.9 crore as against Rs 240.9 crore
    • EBITDA at Rs 31.9 crore as against Rs 27.9 crore
      • EBITDA margin at 13.5% as against 11.6%
    • PAT stood at Rs 17.5 crore as against Rs 15.4 crore
    • EPS (Diluted) stood at Rs 3.2 as against Rs 2.8

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We have reported a stable performance during the quarter despite the ongoing challenging operating environment. All our standalone segments, including HPPC, Textile, and AHN, have reported stable performance. However, our subsidiaries witnessed a slowdown due to subdued demand, leading to lower consolidated HPPC sales during the quarter.

We achieved an improvement in margins on a quarter-over-quarter basis in Q3FY23, supported by moderating raw material costs. Our gross margins increased by 95 bps and EBITDA margins improved by 62 bps, reaching 30.0% and 13.9% respectively. We have been prudently expanding our business with a focus on products with better margins. We are now seeing some stabilization in the market and we look to continue with our growth plans in the coming quarters.

Over the years, our commitment to R&D has been instrumental in establishing Rossari as a leader in the industry. We have a proven track record of developing innovative and customized chemical solutions for customers across various industries. Additionally, the integration of the acquired companies into our R&D efforts has further augmented our technical capabilities.

With a strong focus on R&D, a solid balance sheet, ample capacity, and a comprehensive product portfolio, Rossari are well-positioned to pursue opportunities in the industry. We remain optimistic that a stabilized macroeconomic environment will drive long-term sustainable growth and enable us to deliver a stronger performance in the future”

Result PDF

View Other Company Results



Operating Profit

Profit after Tax


Reserves and Surplus



Operating Profit

Profit after Tax






Equity Capital: 805.16 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,728.09 -29,609.20
LAST 3M 42,048.80 -31,382.80
LAST 6M 65,127.04 16,114.05
LAST 12M 194,271.06 -118,498.61

Rossari Biotech Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Feb 07, 2023 l NSE Announcement

Rossari Biotech Limited - Copy of Newspaper Publication

Feb 06, 2023 l NSE Announcement

NSE Board Meetings Forthcomming

Feb 04, 2023 l NSE Board Meetings Forthcomming

Date Action Type Ratio
Jul 07, 2022 Dividend 25
Sep 08, 2021 Dividend 25


Stock PE (TTM)


Promoter Holding


Book Value







  • Rossari Biotech is one of India’s leading chemical and textile manufacturers. The company’s products are used in the paper, construction, pharmaceutical, animal health, and nutrition industries. It has operations in India, Vietnam, Bangladesh, and Mauritius. The company, founded in 2003, operates two research and development facilities in India. It is headquartered in Mumbai, India. 

    On 22 January 2023, the market capitalisation of the company was Rs 3,926.82 crore. It reported a total revenue of Rs 240.9 crore at the end of the second quarter of the financial year 2022-2023. The company is listed on the Bombay Stock Exchange with the code 543213 and on the National Stock Exchange under the code ROSSARI.   

    Rossari Biotech has a diversified shareholding pattern, with promoters holding approximately 68.44% of the company. The public has a stake of 8.87% in the company. FIIs hold a stake of 8.61% in the company, while DIIs hold 14.08%. The shareholding pattern of the company has remained largely stable over the past year.

    Edward Menezes is the current chairman of the company. Other directors of the company include Sunil Chari, Aseem Dhru, Goutam Bhattacharya, Meher Castelino, Robin Banerjee, and Sharabh Pachory. The chief financial officer of Rossari Biotech is Ketan Sablok. The company’s auditors are Deloitte Haskins & Sells LLP.  

    On 22 January 2023, Rossari Biotech’s share price was Rs 710.85 on the BSE and Rs 710.35 on the NSE. The company’s 52-week-high was Rs 1,283.15, while the 52-week-low was Rs 648.00. Its three-month return to investors was -24.6%, while its one-year return was -43.3%.

    The company’s trailing twelve-month (TTM) revenue was Rs 1,482.97 crore as of 31 December 2022. At the same time, the company had a net profit of Rs 97.70 crore. The company’s P/E TTM was 39.4. The ROE of the company was 16.1, while the ROCE of the company was 22.7.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

No Data Found

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543213
Book Closure Date (Month) :
BSE Group : A
ISIN : INE02A801020

ICICIdirect Rossari Biotech Ltd FAQ

You can buy Rossari Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Rossari Biotech Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Feb 08, 2023 04:01 PM the closing price of Rossari Biotech Ltd was ₹ 683.35.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Feb 08, 2023 04:01 PM, the market cap of Rossari Biotech Ltd stood at ₹ 3,768.81.
The latest PE ratio of Rossari Biotech Ltd as of Feb 08, 2023 04:01 PM is 36.69
The latest PB ratio of Rossari Biotech Ltd as of Feb 08, 2023 04:01 PM is 0.23
The 52-week high of Rossari Biotech Ltd is ₹ 1,196.80 while the 52-week low is ₹ 675.00

Download Our App

market app
market app